Unrelated Allogeneic Stem Cell Transplant in Relapsed/Refractory AML: Widening the Yellow Brick Road

A sizable proportion of patients with acute myeloid leukemia (AML) fail to achieve remission. Hematopoietic stem cell transplantation (HSCT) is the only intervention with potential of long-term survival. A recent Acute Leukemia Working Party (ALWP)/European Society for Blood and Marrow Transplantati...

Full description

Saved in:
Bibliographic Details
Published in:Clinical cancer research 2022-10, Vol.28 (19), p.4167-4170
Main Authors: Adrianzen-Herrera, Diego A, Shastri, Aditi
Format: Article
Language:English
Subjects:
Acute Disease
Hematopoietic Stem Cell Transplantation
Humans
Leukemia, Myeloid, Acute - mortality
Recurrence
Retrospective Studies
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A sizable proportion of patients with acute myeloid leukemia (AML) fail to achieve remission. Hematopoietic stem cell transplantation (HSCT) is the only intervention with potential of long-term survival. A recent Acute Leukemia Working Party (ALWP)/European Society for Blood and Marrow Transplantation (EBMT) analysis reports substantial posttransplant survival gains for patients with active disease who received transplants. Decreased relapse was the largest contributor to survival, a cause for optimism in this challenging population. See related article by Nagler et al., p. 4258.
ISSN:1078-0432
1557-3265
DOI:10.1158/1078-0432.CCR-22-1881